Grace Therapeutics Announces Abstract Highlighting STRIVE-ON Phase 3 Trial Results Accepted for Presentation at AAN 2026
Grace Therapeutics, Inc. (GRCE)
Company Research
Source: GlobeNewswire
PRINCETON, N.J., April 14, 2026 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for intravenous infusion to address significant unmet medical needs in aneurysmal subarachnoid hemorrhage (aSAH) patients, today announced that an abstract highlighting the results from the Company’s STRIVE-ON Phase 3 Safety Trial has been accepted for presentation at the upcoming 2026 American Academy of Neurology annual meeting, to be held April 18-22, 2026 in Chicago, IL. The STRIVE-ON Trial results will be presented as a poster on April 21, 2026. Details are as follows: Session: S21: Neurocritical Care Date: April 21, 2026 Time: 1:00 pm CT Title: Safety and Tolerability of GTX-104 (Nimodipine Injection for IV Infusion) Compared with Oral Nimodipine in Patients with Aneurysmal Subarachnoid Hemorrhage: a Prospective, Ran
Show less
Read more
Impact Snapshot
Event Time:
GRCE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GRCE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GRCE alerts
High impacting Grace Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
GRCE
News
- We're Not Very Worried About Grace Therapeutics' (NASDAQ:GRCE) Cash Burn Rate [Yahoo! Finance]Yahoo! Finance
- Grace Therapeutics to Present Data on the Unmet Medical Needs and Potential Benefits of GTx-104 in the Treatment of aSAH at Upcoming Medical ConferencesGlobeNewswire
- Grace Therapeutics to Participate in the TD Cowen 46th Annual Health Care Conference [Yahoo! Finance]Yahoo! Finance
- Grace Therapeutics to Participate in the TD Cowen 46th Annual Health Care ConferenceGlobeNewswire
- Grace Therapeutics Announces Third Quarter 2026 Financial Results, Provides Business UpdateGlobeNewswire
GRCE
Sec Filings
- 2/17/26 - Form SCHEDULE
- 2/13/26 - Form SCHEDULE
- 2/12/26 - Form 8-K
- GRCE's page on the SEC website